IMVT
Immunovant, Inc.
Next earnings Aug 10, 2026 · consensus $-0.61 EPS
Last earnings +35.3% on 2026-05-20
$38.22
▲ +1.59%$38.22▲ +140.98%
over 1Y
L $14.69EODHDH $38.22
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.6%
1W+10.1%
1M+13.0%
3M+54.4%
YTD+47.5%
1Y+141.0%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 24 analysts
Buy
Clinical-stage FcRn play with no revenue and a $506M loss; a recent Phase 3 failure narrows it to a single binary bet on IMVT-1402.
Immunovant is a pre-revenue, clinical-stage immunology company whose value rests entirely on IMVT-1402, a potentially best-in-class anti-FcRn antibody for IgG-mediated autoimmune diseases. The financials are pure cash-burn: no product revenue, a -$506M net loss (EPS -$2.77), -$407M operating cash burn, and a -$1.75B accumulated deficit. The company itself states current funds 'will not be sufficient' to complete development and launch across all indications it is evaluating, and expects to keep incurring losses for the foreseeable future.
Sources: SEC EDGAR (CIK 0001764013, latest 10-K filed 2026-05-20) · EODHD · analysis by claude-code · as of 6/21/2026, 8:53:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.